Clovis Oncology (CLVS) Posts Smaller Q2 Loss, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Clovis Oncology Announces Second Quarter 2017 Operating Results
August 2, 2017 4:05 PM EDTStrong second quarter of launch for Rubraca® (rucaparib) in U.S. with $14.6M reported in net sales Positive topline data from the ARIEL3 study reported on June 19, 2017; presentation of full dataset confirmed at European Society for Medical Oncology 2017 Congress in Madrid Clovis plans to submit a supplemental New Drug Application (sNDA) for a second-line and later maintenance treatment indication before the end of October Rucaparib E.U. Marketing Authorization Application under review; establishing E.U. organization to support a potential European launch... More
